Treating obesity to improve the quality of two lives: a case report

Česká verzia

Authors: Norbert Nagy ¹; Patrícia Kleinová ^1,2; Tímea Blichová ^1,2; Matej Vnučák ^1,2; Karol Graňák ^1,2; Monika Beliančinová ^1,2; Tomáš Bolek ¹; Matej Samoš ¹; Martin Jozef Péč ¹; Jakub Jurica ¹; Patrik Lecký ¹; Zuzana Miertová ¹; Marián Mokáň ¹; Ivana Dedinská ^1,2
Authors place of work: I. interná klinika JLF UK a UNM, Martin ¹; Transplantačno-nefrologické oddelenie UNM, Martin ²
Published in the journal: Forum Diab 2024; 13(2): 102-105
Category: Case Report

Summary

Obesity treatment is a big topic nowadays. Many treatment options are known, and their use varies based on BMI. Regimen measures are the mainstay, followed by pharmacological and invasive procedures. Obesity is one of the common contraindications in patients undergoing kidney transplantation. Data in the treatment of obesity in the potential kidney donor are scarce. We present the case of a 63-year-old female patient who was successfully treated with a GLP-1 receptor agonist and may be a kidney donor.

Keywords:

obesity – Transplantation – kidney – body mass index

Zdroje

World Health Organization. WHO The challenge of obesity. Dostupné z WWW: <https://www.who.int/europe/news-room/fact-sheets/item/the-challenge-of-obesity>.

Mehmet K, Sidar C, Duygu U et al. Donor obesity and weight gain after transplantation: two still overlooked threats to long-term graft survival. Clin Kidney J 2023; 16(2): 254–261. Dostupné z DOI: <https://doi.org/10.1093/ckj/sfac216>.

Chadban SJ, Ahn C, Axelrod DA et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation 2020; 104(4S1): S11-S103. Dostupné z DOI: <https://doi 10.1097/TP.0000000000003136>.

Jackson VM, Breen DM, Fortin JP et al. Latest approaches for the treatment of obesity. Expert Opin Drug Discov 2015; 10(8): 825–839. Dostupné z DOI: <https://doi:10.1517/17460441.2015.1044966>.

Müller TD, Finan B, Bloom SR et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019; 30:72–130. Dostupné z DOI: <https://doi: 10.1016/j.molmet.2019.09.010>.

Branco AW, Branco Filho AJ, Kondo W. Laparoscopic live donor nephrectomy in patients surgically treated for morbid obesity. Int Braz J Urol 2007; 33(3): 377–379. Dostupné z DOI: <https://doi 10.1590/s1677–55382007000300010>.

Cook SA, MacLaughlin H, Macdougall IC. A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease. Nephrol Dial Transplant 2008; 23(1): 263–268. Dostupné z DOI: <https://doi: 10.1093/ndt/gfm511>. PMID: 17977872.

MacLaughlin HL, Hall WL, Condry J et al. Participation in a structured weight loss program and all-cause mortality and cardiovascular morbidity in obese patients with chronic kidney disease. J Ren Nutr 2015; 25(6): 472–479. Dostupné z DOI: <https://doi: 10.1053/j.jrn.2015.05.001>.

Apovian CM, Aronne L, Rubino D et al. [COR-II Study Group]. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013; 21(5): 935–943. Dostupné z DOI: <https://doi: 10.1002/oby.20309>.

Pi-Sunyer X, Astrup A, Fujioka K. [SCALE Obesity and Prediabetes NN8022–1839 Study Group]. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373(1): 11–22. Dostupné z DOI: <https://doi: 10.1056/NEJMoa1411892>. PMID: 26132939.

Garvey WT, Batterham RL, Bhatta M. [STEP 5 Study Group]. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28(10): 2083–2091. Dostupné z DOI: <https://doi: 10.1038/s41591–022–02026–4>. PMID: 36216945. PMCID: PMC9556320.